By Laurence P. Birch, Chairman and CEO, DATATRAK
I read a discussion on LinkedIn recently where someone asked for feedback on eClinical solutions to the community of members. The initial question focused on market share in the industry, by company.
There is no doubt that when it comes to market share, the perception is Bigger is Better. Makes sense, on some level, that the solution that sells the most has to be the best.
But that simply isn’t true.
Sure, if you select either of the most purchased platforms in the eClinical industry, namely Oracle InForm or Medidata Rave, you won’t get fired. But if you have the foresight to break out of that rut and actually consider the benefits of other solutions, and yes, namely, DATATRAK ONE®,
you may actually get promoted.
The reality is in most industries – I would suggest nearly all – technology-driven solutions are transforming productivity and improving efficiency. Industries from manufacturing to music are not only open to but clamoring for new technology to resolve both old and new pain points. And the companies that are doing that are winning, and shaking up the old standbys. The end result? More efficient and effective processes from all suppliers in the industry and a better outcome for their users.
Looking at the eClinical industry, new solutions are making real differences to reduce the time and cost required to bring meaningful treatments to those in need. But our industry is slow to change—why? I think because companies are so weary of the complications and difficulty of using the current systems, that they are afraid that change will be risky and hard to manage---and the big players promote that change will be very, very difficult. Think about that folks; marketing through fear is not a good business model. IBM did that for years until customers realized that it simply wasn’t true. The perception that change is difficult and expensive in the eClinical space is equally misplaced. The reality is just the opposite, at least with DATATRAK
I won’t go in to how we do it here, but our approach to Clinical Trial Data Collection and Management IS better: we DO remove complexities. Our solutions are SIMPLE to use - and that means faster, easier training too!
The core of our ease-of-use and training is our Unified Platform. There are no required data moves, no integration between solutions, with all data visible on every solution, all the time. For example, when trial changes occur, and they do, the UNIFIED nature of our platform allows for faster, less expensive validation. These features deliver real benefits –driving cost and complexity OUT of the trial - and improving patient safety. If our goal as an industry is to allow people to live longer and better lives through successful drug development, shouldn’t that start with the safety of the patient in the drug trials? We at DATATRAK
think so—and we know you do too.
We are making headway changing the perception of the industry. Those who have had the foresight to look beyond the top 2 providers and move to DATATRAK
have had great results, and more of our clients are moving from trial-by-trial to enterprise agreements. Fully 100% of our clients use 2 or more DATATRAK
solutions, and 67% use 3 or more. They are experiencing the benefits of the Unified Platform – something the top 2 can’t offer.
UX is a GLOBAL platform and being used around the world; we are a leading eClinical solutions and services provider with growing business in all trial phases with all types of clinical trials. We have embraced CDISC standards and our executive team has over 100+ years of life sciences experiences, with a deep understanding of clinical research that we have leveraged to build a truly superior solution to address the needs of clinical trials.
So come on over. Sit in on a demo. We guarantee you will see the rewards are great if you look past the top 2.
Because Bigger Isn’t Always Better. DATATRAK
This blog contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as well as historical information. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual, results, performance or achievements, or industry results, to be materially different from anticipated results, performance or achievements expressed or implied by such forward-looking statements. When used in this blog, statements that are not statements of current or historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “plan,” “intend,” “may,” “will,” “expect,” “believe,” “could,” “anticipate,” “estimate,” or “continue” or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. For a list of certain factors that may cause actual results to differ from those contemplated in forward-looking statements, please see the Company’s periodic reports filed with the OTCQX Market. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.